The DOI matches its Crossref record; 186 of the 188 references it cites were found in a registry or an index.
The Hippo Signaling Pathway in Drug Resistance in Cancer
Open accessAbstract
Chemotherapy represents one of the most efficacious strategies to treat cancer patients, bringing advantageous changes at least temporarily even to those patients with incurable malignancies. However, most patients respond poorly after a certain number of cycles of treatment due to the development of drug resistance. Resistance to drugs administrated to cancer patients greatly limits the benefits that patients can achieve and continues to be a severe clinical difficulty. Among the mechanisms which have been uncovered to mediate anti-cancer drug resistance, the Hippo signaling pathway is gaining increasing attention due to the remarkable oncogenic activities of its components (for example, YAP and TAZ) and their druggable properties. This review will highlight current understanding of how the Hippo signaling pathway regulates anti-cancer drug resistance in tumor cells, and currently available pharmacological interventions targeting the Hippo pathway to eradicate malignant cells and potentially treat cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Upon activation, YAP/TAZ bind to the TEAD family of transcriptional factors to induce the expression of genes that promote cell proliferation and inhibit apoptosis, leading to resistance to cancer therapy (Figure 1) [100].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yao, W., Zhu, S., Li, P., & Zhang, S. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0812-3 · Cited by 18 · cited 2×
“gation factor 1 (MIEF1) via c-Jun N-terminal kinase (JNK) pathway, thus amplifying fatal mitochondrial stress [89].”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000 · cited 1×
“Disrupted mitotic spindles are not able to satisfy the spindle assembly check point, leading to mitotic arrest and eventually cell death, at least in in vitro models [50,51].”
BackgroundZhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770 · cited 1×
“Although combinations of multiple therapeutic agents have become the paradigm for cancer therapy as initial solutions to the resistance against single-agent treatment, drug resistance continues to be a huge obstacle [1].”
Background
Cited by
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
“256 For example, YAP and TAZ overexpression or YAP nuclear translocation could decrease the ef fi cacy of cisplatin, 257 , doxorubicin, 258 5-fl uoracil 259,260 and Taxol, 261 while MST1 and LATS1/2 downregulation resulted in resistance to cisplatin 262 and 5-fl uoracil.”
BackgroundQKI shuttles internal m7G-modified transcripts into stress granules and modulates mRNA metabolism
Zhao, Z., Qing, Y., Dong, L., Han, L., Wu, D., Li, Y., Li, W., Xue, J., Zhou, K., Sun, M., et al. (2023) · Cell · doi:10.1016/j.cell.2023.05.047 · Cited by 188
Control of stem cell renewal and fate by YAP and TAZ
Driskill, J. H., & Pan, D. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00644-5 · Cited by 158
Messina, B., Sardo, F. L., Scalera, S., Memeo, L., Colarossi, C., Mare, M., Blandino, G., Ciliberto, G., Maugeri‐Saccà, M., & Bon, G. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05568-8 · Cited by 122
“As a result, the aberrant YAP/TAZ transcriptional activity was connected to invasion and distant dissemination [20–23], chemoresistance [24, 25], and maintenance/expansion of the cancer stem cell (CSCs) compartment [26–29].”
BackgroundKoltai, T., Reshkin, S. J., Carvalho, T. M. A., Molfetta, D. D., Greco, M. R., Alfarouk, K. O., & Cardone, R. A. (2022) · Cancers · doi:10.3390/cancers14102486 · Cited by 129
“found that this pathway plays a role in drug resistance [115,447].”
Background
Metadata
- Authors
- Zeng, R., & Dong, J.
- Affiliations
- Fred and Pamela Buffett Cancer Center (US)
- Corresponding author
- Dong, Jixin
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-01-16
- Volume
- 13
- Issue
- 2
- Pages
- 318
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7830227
- OpenAlex
- W3121345014
- Cited by
- 89
- References
- 188
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 17 · 2023: 15 · 2022: 13 · 2021: 10
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (R01 GM109066, P30 CA036727)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- Hippo signaling pathway, drug resistance, chemoresistance, YAP, TAZ, cancer, pharmacological targeting, cancer cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Hippo Signaling Pathway in Drug Resistance in Cancer. https://app.cochat.ai/papers/10.3390/cancers13020318
- The paper
- Zeng, R., & Dong, J. (2021). The Hippo Signaling Pathway in Drug Resistance in Cancer. Cancers. https://doi.org/10.3390/cancers13020318
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.